Filing summary
Entity discrepancy: The supplied filing is Unum Therapeutics Inc.’s Form 10-Q, not a filing under the name Cogent Biosciences, Inc. It reports the quarter ended March 31, 2018 and was signed May 14, 2018.
Business context
Unum was a clinical-stage biotechnology company developing ACTR engineered T-cell therapies for cancer. It had no approved products and no product sales; reported revenue came from its Seattle Genetics collaboration. Its lead program, ACTR087 with rituximab, was in Phase I, alongside ACTR707 with rituximab and ACTR087 with SEA-BCMA.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 / prior date |
|---|---|---|
| Collaboration revenue | $2.22 million | $1.83 million |
| Research and development expense | $8.14 million | $6.95 million |
| General and administrative expense | $1.06 million | $0.94 million |
| Operating loss | $6.99 million | $6.07 million |
| Net loss | $6.74 million | $5.94 million |
| Net loss per share | $0.66 | $0.58 |
| Operating cash used | $7.98 million | $7.27 million |
At March 31, 2018, cash and cash equivalents were $25.7 million and marketable securities were $6.7 million, totaling $32.4 million. Working capital was $12.3 million; total liabilities were $27.5 million. The company had no debt outstanding, although it had access to up to $15.0 million under a secured loan facility. There was no meaningful product gross margin disclosed, and profitability metrics are not applicable to the company’s pre-commercial business.
Cash, cash equivalents and restricted cash declined by $2.6 million during the quarter to $27.0 million. Investing activities provided $5.9 million, mainly from marketable-security maturities and sales; financing activities used $0.5 million, primarily for offering costs.
Material changes and unusual items
- Operating expenses rose $1.31 million year over year, led by $1.19 million higher R&D spending. Spending increased on ACTR707/rituximab and ACTR087/SEA-BCMA trials and related manufacturing and clinical activity, while ACTR087/rituximab direct costs declined.
- Revenue increased $0.39 million year over year. Adoption of ASC 606 on January 1, 2018 changed collaboration revenue recognition from straight-line to a cost-to-cost method. The new method reduced Q1 2018 reported revenue by $0.44 million versus the prior standard and increased opening deferred revenue and accumulated deficit by $6.19 million.
- After quarter-end, the April 3 IPO raised $64.4 million net of underwriting discounts and commissions but before offering costs. Seattle Genetics invested $5.0 million in a concurrent private placement; an April 25 partial over-allotment added approximately $2.4 million net. Preferred stock converted to common stock upon the IPO. These proceeds were not included in March 31 cash.
- Management said post-financing cash and marketable securities were expected to fund operations through at least December 2019, excluding available borrowings. The filing also states the company would need additional funds to complete planned ACTR087 Phase II work in patients previously treated with CD19 CAR-T and the planned ACTR707/trastuzumab Phase I trial.
Outlook, risks and contingencies
Management expected operating losses and expenses to increase as clinical development, manufacturing capabilities, staffing and public-company costs expanded. Revenue for the coming years was expected primarily from the Seattle Genetics collaboration; timing and receipt of future milestones or royalties were uncertain. The collaboration’s remaining performance obligation was estimated at $76.0 million, expected to be recognized through December 2022; this is not a forecast of cash receipts.
Key risks include early-stage clinical and regulatory uncertainty, patient-specific cell manufacturing and third-party supply dependence, competition, intellectual-property protection, and the need for further financing. In the ACTR087/rituximab Phase I trial, two of 17 treated patients had ACTR087-related severe cytokine release syndrome and one had ACTR087-related neurotoxicity that was fatal. Fatal sepsis events were also reported in two patients, with one considered related to ACTR087 and one not related. The FDA clinical hold imposed in December 2017 was lifted in February 2018 after review; protocol and dosing changes were made. The company cautioned that serious safety events could recur.
Other disclosed obligations include $9.9 million of future minimum operating lease payments and $0.9 million of non-cancelable manufacturing commitments over the following 12 months. No material legal proceedings were reported. Management concluded disclosure controls were effective as of March 31, 2018.
Important facts for investors to verify
- Confirm the issuer identity: the supplied document names Unum Therapeutics Inc.; verify whether this is the intended filing for Cogent Biosciences.
- Review subsequent clinical updates, including safety, efficacy, enrollment and the status of the ACTR087/rituximab trial after the FDA hold was lifted.
- Check actual post-IPO cash, offering costs, subsequent spending and any later financing against the stated runway through December 2019.
- Assess the assumptions and timing behind ASC 606 revenue recognition and the $76.0 million remaining collaboration performance obligation.
- Track whether additional capital was secured for the Phase II and ACTR707/trastuzumab trials, and review any resulting dilution or changes to plans.